S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:EPIX

ESSA Pharma (EPIX) Stock Price, News & Analysis

$9.15
-0.32 (-3.38%)
(As of 03/4/2024 ET)
Today's Range
$8.92
$9.56
50-Day Range
$6.17
$10.65
52-Week Range
$2.56
$11.67
Volume
61,161 shs
Average Volume
200,750 shs
Market Capitalization
$404.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

ESSA Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
80.3% Upside
$16.50 Price Target
Short Interest
Healthy
5.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of ESSA Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Decreasing
From ($0.80) to ($1.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.10 out of 5 stars

Medical Sector

401st out of 948 stocks

Pharmaceutical Preparations Industry

184th out of 434 stocks


EPIX stock logo

About ESSA Pharma Stock (NASDAQ:EPIX)

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

EPIX Stock Price History

EPIX Stock News Headlines

ESSA Pharma: Q1 Earnings Insights
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Recap: ESSA Pharma Q4 Earnings
See More Headlines
Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/04/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EPIX
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.50
High Stock Price Target
$17.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+74.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-26,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.30 per share

Miscellaneous

Free Float
37,735,000
Market Cap
$418.95 million
Optionable
Optionable
Beta
1.64

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. David Ross Parkinson M.D. (Age 74)
    President, CEO & Director
    Comp: $814.15k
  • Mr. David S. Wood C.M.A. (Age 67)
    CPA, CMA, CPA, M.B.A., MBA, Chief Financial Officer
    Comp: $590.39k
  • Mr. Peter A. Virsik M.B.A. (Age 53)
    M.S., Executive VP & COO
    Comp: $645.95k
  • Dr. Alessandra Cesano M.D. (Age 63)
    Ph.D., Chief Medical Officer & Executive VP
    Comp: $623.93k
  • Chandtip Chandhasin
    Executive
  • Erica Osbourne
    Executive
  • Erin Rudsinski
    Executive
  • Loleta Harris
    Executive
  • Neil Thapar
    Executive
  • Nkengyal Barber
    Executive














EPIX Stock Analysis - Frequently Asked Questions

Should I buy or sell ESSA Pharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EPIX shares.
View EPIX analyst ratings
or view top-rated stocks.

What is ESSA Pharma's stock price target for 2024?

2 Wall Street research analysts have issued 12 month price objectives for ESSA Pharma's stock. Their EPIX share price targets range from $16.00 to $17.00. On average, they predict the company's share price to reach $16.50 in the next year. This suggests a possible upside of 80.3% from the stock's current price.
View analysts price targets for EPIX
or view top-rated stocks among Wall Street analysts.

How have EPIX shares performed in 2024?

ESSA Pharma's stock was trading at $6.60 at the start of the year. Since then, EPIX stock has increased by 38.6% and is now trading at $9.15.
View the best growth stocks for 2024 here
.

Are investors shorting ESSA Pharma?

ESSA Pharma saw a decrease in short interest in February. As of February 15th, there was short interest totaling 1,130,000 shares, a decrease of 19.9% from the January 31st total of 1,410,000 shares. Based on an average trading volume of 153,500 shares, the short-interest ratio is currently 7.4 days. Approximately 5.6% of the shares of the stock are short sold.
View ESSA Pharma's Short Interest
.

When is ESSA Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EPIX earnings forecast
.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.03.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX).

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include PFM Health Sciences LP (7.39%), RTW Investments LP (5.21%), BNP Paribas Financial Markets (0.13%), Royal Bank of Canada (0.07%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger, Growth N V Biotech and Peter Virsik.
View institutional ownership trends
.

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EPIX) was last updated on 3/4/2024 by MarketBeat.com Staff